While semaglutide remains on the shortage list, Novo Nordisk noted last week that the last remaining ... and that counterfeit forms of Ozempic are being sold. Semaglutide and a similar GLP-1 drug, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

With the rise in the popularity of weight loss drugs like ‘Wegovy’ and ‘Ozempic,’ we’re learning a counterfeit market has ...

In recent health news, Chinese scientists stress the need for regional diets to combat obesity, U.S. minority veterans ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

A study reveals racial and ethnic disparities in access to Novo Nordisk's diabetes and weight loss drugs among U.S. military veterans. Black, Asian, and Native American patients are less likely to ...

U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...

The drugs whose labels were updated include Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro. The agency said, ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...